Skip to main content
. 2021 Feb 24;13(5):944. doi: 10.3390/cancers13050944

Figure 1.

Figure 1

Identification and validation of ERK5 as a novel temozolomide (TMZ) resistance factor in GBM. (A): TMZ cytotoxicity as assessed by MTT assays in the indicated glioblastoma cell lines transfected with either control or ERK5 siPOOLs. (B): TMZ cytotoxicity as assessed by MTT assays in the indicated glioblastoma cell lines pretreated with either DMSO or 250 nM of the ERK5-in-1 small molecule ERK5 inhibitor. (C): TMZ cytotoxicity as assessed by clonogenic survival assays in the respective MGMT +ve LN18 and MGMT −ve U-251 glioblastoma cells pretreated with either DMSO or 250 nM of the ERK5-in-1 small molecule ERK5 inhibitor. (D): TMZ cytotoxicity as assessed by clonogenic survival assays in the indicated glioblastoma cell lines pretreated with either DMSO or 10 μM of the AX15836 small molecule ERK5 inhibitor. All data shown are the means derived from at least three independent experimental repeats together with their associated standard errors. Statistical significance was calculated using the nonparametric Mann–Whitney U-test: ns = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, and **** = p < 0.0001 comparing the indicated treatment to DMSO controls or to another indicated treatment cell population.